HRP20130764T1 - Mutacije k-ras i b-raf i lijeäśenje anti-egfr antitijelima - Google Patents
Mutacije k-ras i b-raf i lijeäśenje anti-egfr antitijelima Download PDFInfo
- Publication number
- HRP20130764T1 HRP20130764T1 HRP20130764AT HRP20130764T HRP20130764T1 HR P20130764 T1 HRP20130764 T1 HR P20130764T1 HR P20130764A T HRP20130764A T HR P20130764AT HR P20130764 T HRP20130764 T HR P20130764T HR P20130764 T1 HRP20130764 T1 HR P20130764T1
- Authority
- HR
- Croatia
- Prior art keywords
- tumor
- raf
- ras
- mutation
- absence
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title claims 13
- 101710113436 GTPase KRas Proteins 0.000 title claims 12
- 238000009175 antibody therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 16
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 9
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 108060006698 EGF receptor Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102200006532 rs112445441 Human genes 0.000 claims 2
- 102220197833 rs112445441 Human genes 0.000 claims 2
- 102200006531 rs121913529 Human genes 0.000 claims 2
- 102200006537 rs121913529 Human genes 0.000 claims 2
- 102200006539 rs121913529 Human genes 0.000 claims 2
- 102200006538 rs121913530 Human genes 0.000 claims 2
- 102200006541 rs121913530 Human genes 0.000 claims 2
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Metoda redikcije izostajanja odgovora tumora na liječenje antitijelom na EGFr, naznačena time, što podrazumijeva određivanje prisustva ili odsustva mutacije B-raf V600E u uzorku spomenutog tumora; pri čemu prisustvo mutacije B-raf ukazuje na to da tumor neće odgovoriti na liječenje antitijelom na EGFr.
2. Metoda iz zahtjeva 1, naznačena time, što podrazumijeva još i određivanje prisustva ili odsustva mutacije K-ras u uzorku spomenutog tumora, pri čemu se mutacija K-ras bira između G12S, G12V, G12D, G12A, G12C, G13A i G13D; pri čemu prisustvo mutacije K-ras ukazuje na to da tumor neće odgovoriti na liječenje antitijelom na EGFr.
3. Metoda predikcije izostajanja odgovora na liječenje antitijelom na EGFr kod pacijenta, naznačena time, što podrazumijeva određivanje prisustva ili odsustva mutacije B-raf V600E u uzorku tumora uzetom od spomenutog pacijenta; pri čemu prisustvo mutacije B-raf ukazuje na to da pacijent neće odgovoriti na liječenje antitijelom na EGFr.
4. Metoda iz zahtjeva 3, naznačena time, što podrazumijeva još i određivanje prisustva ili odsustva mutacije K-ras u uzorku tumora uzetom od spomenutog pacijenta, pri čemu se K-ras mutacija bira između G12S, G12V, G12D, G12A, G12C, G13A i G13D; pri čemu prisustvo mutacije K-ras ukazuje na to da pacijent neće odgovoriti na liječenje antitijelom na EGFr.
5. Metoda iz zahtjeva 1, 2, 3 ili 4, naznačena time, što je antitijelo na EGFr panitumumab.
6. Metoda iz bilo kojeg od zahtjeva 1 do 5, naznačena time, što tumor je tumor kolona ili rektuma.
7. Metoda iz bilo kojeg od zahtjeva 1 do 6, naznačena time, što se tumor dobija od pacijenta koji pati od metastatskog kancera kolona.
8. Metoda iz bilo kojeg od zahtjeva 1 do 7, naznačena time, što određivanje prisustva ili odsustva mutacije B-raf i/ili K-ras u tumoru ili u uzorku spomenutog tumora podrazumijeva amplifikaciju B-raf i/ili K-ras nukleinske kiseline iz tumora ili uzorka spomenutog tumora i sekvencioniranje amplifirane nukleinske kiseline.
9. Metoda iz bilo kojeg od zahtjeva 1 do 7, naznačena time, što određivanje prisustva ili odsustva mutacije B-raf i/ili K-ras u tumoru ili u uzorku spomenutog tumora podrazumijeva detektiranje mutantnog B-raf i/ili K-ras polipeptida u uzorku tumora korištenjem sredstva koje se specifično vezuje za mutantni B-raf i/ili K-ras polipeptid.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90697607P | 2007-03-13 | 2007-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130764T1 true HRP20130764T1 (hr) | 2013-10-25 |
Family
ID=39666021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130764AT HRP20130764T1 (hr) | 2007-03-13 | 2013-08-12 | Mutacije k-ras i b-raf i lijeäśenje anti-egfr antitijelima |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20090075267A1 (hr) |
| EP (2) | EP2412828B1 (hr) |
| JP (3) | JP2010521154A (hr) |
| AR (1) | AR065686A1 (hr) |
| AU (1) | AU2008226808B2 (hr) |
| CA (1) | CA2680330A1 (hr) |
| CL (1) | CL2008000716A1 (hr) |
| CY (1) | CY1114159T1 (hr) |
| DK (1) | DK2412828T3 (hr) |
| ES (1) | ES2426814T3 (hr) |
| HK (1) | HK1167005A1 (hr) |
| HR (1) | HRP20130764T1 (hr) |
| MX (1) | MX2009009779A (hr) |
| PE (1) | PE20090690A1 (hr) |
| PL (1) | PL2412828T3 (hr) |
| PT (1) | PT2412828E (hr) |
| RS (1) | RS52932B (hr) |
| SI (1) | SI2412828T1 (hr) |
| TW (1) | TW200904828A (hr) |
| WO (1) | WO2008112274A2 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| ITBO20050646A1 (it) | 2005-10-26 | 2007-04-27 | Silicon Biosystem S R L | Metodo ed apparato per la caratterizzazione ed il conteggio di particelle |
| CN103424541B (zh) | 2006-05-18 | 2018-01-30 | 分子压型学会股份有限公司 | 确定针对病状的个性化医疗介入的系统和方法 |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| SI2412828T1 (sl) * | 2007-03-13 | 2013-10-30 | Amgen Inc. | Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr |
| PL2121989T5 (pl) * | 2007-03-13 | 2023-03-06 | Amgen Inc. | Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR |
| ITTO20070771A1 (it) | 2007-10-29 | 2009-04-30 | Silicon Biosystems Spa | Metodo e apparato per la identificazione e manipolazione di particelle |
| US8583380B2 (en) | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| US10895575B2 (en) | 2008-11-04 | 2021-01-19 | Menarini Silicon Biosystems S.P.A. | Method for identification, selection and analysis of tumour cells |
| IT1391619B1 (it) | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
| CN102301002A (zh) * | 2008-11-12 | 2011-12-28 | 卡里斯生命科学卢森堡控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
| EP3722810A3 (en) * | 2009-02-11 | 2021-01-13 | Caris MPI, Inc. | Molecular profiling of tumors |
| CN101487051B (zh) * | 2009-02-24 | 2011-07-20 | 广州益善生物技术有限公司 | Braf基因突变的检测探针、液相芯片及其检测方法 |
| DK2408562T3 (en) | 2009-03-17 | 2018-06-06 | Menarini Silicon Biosystems Spa | Microfluidic device for isolating cells |
| WO2011028540A1 (en) * | 2009-08-24 | 2011-03-10 | Genentech, Inc. | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
| WO2011031840A1 (en) * | 2009-09-09 | 2011-03-17 | Quintiles Transnational Corp. | Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders |
| CN102115782B (zh) * | 2009-12-30 | 2014-06-18 | 北京雅康博生物科技有限公司 | 用于定量检测K-ras突变的试剂盒 |
| JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
| US20110217309A1 (en) * | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
| JP2013523178A (ja) * | 2010-04-12 | 2013-06-17 | レスポンス ジェネティクス，インコーポレイティド | Ｋｒａｓプライマーおよびプローブ |
| CA2804335A1 (en) | 2010-06-15 | 2011-12-22 | Alberto Bardelli | Mlk4 gene, a new diagnostic and prognostic marker in cancers |
| EP2619329B1 (en) | 2010-09-24 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
| WO2012049279A1 (en) | 2010-10-14 | 2012-04-19 | Universitaet Des Saarlandes | MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs |
| AU2012239997A1 (en) | 2011-04-07 | 2013-10-17 | Amgen Inc. | Novel EGFR binding proteins |
| ITTO20110990A1 (it) | 2011-10-28 | 2013-04-29 | Silicon Biosystems Spa | Metodo ed apparato per l'analisi ottica di particelle a basse temperature |
| US9023640B2 (en) * | 2011-12-13 | 2015-05-05 | Fundamental Solutions Corporation | Device for rapid detection of infectious agents |
| BR112015003418A2 (pt) | 2012-08-17 | 2017-07-04 | Hoffmann La Roche | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. |
| CA2886397A1 (en) * | 2012-09-26 | 2014-04-03 | Insight Genetics, Inc. | Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers |
| JP6520705B2 (ja) * | 2013-03-19 | 2019-05-29 | 凸版印刷株式会社 | Ｅｇｆｒ阻害剤感受性予測方法 |
| JP6512828B2 (ja) | 2014-01-07 | 2019-05-15 | 三星電子株式会社Ｓａｍｓｕｎｇ Ｅｌｅｃｔｒｏｎｉｃｓ Ｃｏ．，Ｌｔｄ． | ｃ−Ｍｅｔ阻害剤の効能予測または効能検証のためのバイオマーカー |
| WO2015175705A1 (en) | 2014-05-13 | 2015-11-19 | Board Of Regents, The University Of Texas System | Gene mutations and copy number alterations of egfr, kras and met |
| KR20160037666A (ko) | 2014-09-29 | 2016-04-06 | 삼성전자주식회사 | KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측 |
| US10471183B2 (en) | 2015-12-22 | 2019-11-12 | Access Vascular, Inc. | High strength biomedical materials |
| US11577008B2 (en) | 2017-06-21 | 2023-02-14 | Access Vascular, Inc. | High strength porous materials incorporating water soluble polymers |
| CN107918013A (zh) * | 2017-09-25 | 2018-04-17 | 浙江天科高新技术发展有限公司 | 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒 |
| CN108085390A (zh) * | 2017-12-29 | 2018-05-29 | 上海桐树生物科技有限公司 | 肿瘤驱动基因变异的检测剂、检测试剂盒及其应用 |
| EP4171704A1 (en) | 2020-06-30 | 2023-05-03 | Access Vascular, Inc. | Articles comprising markings and related methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69322266T2 (de) | 1992-04-03 | 1999-06-02 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
| US5470705A (en) | 1992-04-03 | 1995-11-28 | Applied Biosystems, Inc. | Probe composition containing a binding domain and polymer chain and methods of use |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP1161563A2 (en) | 1999-03-15 | 2001-12-12 | PE Corporation (NY) | Probe/mobility modifier complexes for multiplex nucleic acid detection |
| EP1313880A2 (en) | 2000-05-30 | 2003-05-28 | PE Corporation (NY) | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| MXPA04011550A (es) | 2002-05-20 | 2005-02-17 | Abgenix Inc | Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico. |
| ES2741574T3 (es) * | 2004-03-31 | 2020-02-11 | Massachusetts Gen Hospital | Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| JP2008535477A (ja) | 2005-02-24 | 2008-09-04 | アムジエン・インコーポレーテツド | 上皮成長因子受容体変異 |
| JP2008536493A (ja) * | 2005-04-01 | 2008-09-11 | アムジエン・インコーポレーテツド | 上皮増殖因子受容体遺伝子のコピー数 |
| BRPI0610440A2 (pt) * | 2005-04-14 | 2010-06-22 | Merck Patent Gmbh | terapia com anticorpo anti-egfr baseada em um maior número de cópias do gene egfr em tecidos de tumores |
| JP2008546421A (ja) * | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | Ｅｇｆｒおよびｋｒａｓ変異 |
| US7908091B2 (en) * | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| CN101501803B (zh) * | 2006-08-10 | 2011-08-03 | 株式会社生方制作所 | 热响应开闭器 |
| SI2412828T1 (sl) * | 2007-03-13 | 2013-10-30 | Amgen Inc. | Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr |
| PL2121989T5 (pl) * | 2007-03-13 | 2023-03-06 | Amgen Inc. | Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR |
-
2008
- 2008-03-11 SI SI200831031T patent/SI2412828T1/sl unknown
- 2008-03-11 MX MX2009009779A patent/MX2009009779A/es active IP Right Grant
- 2008-03-11 AR ARP080100994A patent/AR065686A1/es unknown
- 2008-03-11 JP JP2009553625A patent/JP2010521154A/ja not_active Withdrawn
- 2008-03-11 PL PL11184356T patent/PL2412828T3/pl unknown
- 2008-03-11 CL CL200800716A patent/CL2008000716A1/es unknown
- 2008-03-11 PE PE2008000450A patent/PE20090690A1/es not_active Application Discontinuation
- 2008-03-11 US US12/046,312 patent/US20090075267A1/en not_active Abandoned
- 2008-03-11 CA CA002680330A patent/CA2680330A1/en not_active Abandoned
- 2008-03-11 RS RS20130374A patent/RS52932B/en unknown
- 2008-03-11 AU AU2008226808A patent/AU2008226808B2/en not_active Ceased
- 2008-03-11 TW TW097108518A patent/TW200904828A/zh unknown
- 2008-03-11 ES ES11184356T patent/ES2426814T3/es active Active
- 2008-03-11 EP EP11184356.1A patent/EP2412828B1/en not_active Revoked
- 2008-03-11 WO PCT/US2008/003327 patent/WO2008112274A2/en active Application Filing
- 2008-03-11 EP EP08742064A patent/EP2118322A2/en not_active Withdrawn
- 2008-03-11 PT PT111843561T patent/PT2412828E/pt unknown
- 2008-03-11 DK DK11184356.1T patent/DK2412828T3/da active
-
2010
- 2010-05-17 HK HK12107511.1A patent/HK1167005A1/xx not_active IP Right Cessation
- 2010-12-22 US US12/976,895 patent/US20110212456A1/en not_active Abandoned
-
2013
- 2013-07-19 CY CY20131100612T patent/CY1114159T1/el unknown
- 2013-08-12 HR HRP20130764AT patent/HRP20130764T1/hr unknown
- 2013-09-12 JP JP2013189299A patent/JP5905422B2/ja active Active
-
2015
- 2015-02-23 JP JP2015032611A patent/JP2015119726A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2412828B1 (en) | 2013-06-05 |
| RS52932B (en) | 2014-02-28 |
| TW200904828A (en) | 2009-02-01 |
| DK2412828T3 (da) | 2013-09-02 |
| AR065686A1 (es) | 2009-06-24 |
| CL2008000716A1 (es) | 2008-09-22 |
| EP2412828A1 (en) | 2012-02-01 |
| WO2008112274A2 (en) | 2008-09-18 |
| AU2008226808A1 (en) | 2008-09-18 |
| CY1114159T1 (el) | 2016-08-31 |
| EP2118322A2 (en) | 2009-11-18 |
| SI2412828T1 (sl) | 2013-10-30 |
| ES2426814T3 (es) | 2013-10-25 |
| CA2680330A1 (en) | 2008-09-18 |
| JP2013253105A (ja) | 2013-12-19 |
| JP5905422B2 (ja) | 2016-04-20 |
| JP2015119726A (ja) | 2015-07-02 |
| PE20090690A1 (es) | 2009-06-22 |
| US20090075267A1 (en) | 2009-03-19 |
| MX2009009779A (es) | 2009-09-23 |
| HK1167005A1 (en) | 2012-11-16 |
| JP2010521154A (ja) | 2010-06-24 |
| PL2412828T3 (pl) | 2013-11-29 |
| PT2412828E (pt) | 2013-08-02 |
| US20110212456A1 (en) | 2011-09-01 |
| AU2008226808B2 (en) | 2013-04-18 |
| WO2008112274A3 (en) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130764T1 (hr) | Mutacije k-ras i b-raf i lijeäśenje anti-egfr antitijelima | |
| HRP20140360T4 (hr) | K-ras mutacije i terapija anti-egfr antitijelom | |
| Arbour et al. | Treatment outcomes and clinical characteristics of patients with KRAS-G12C–mutant non–small cell lung cancer | |
| Sun et al. | Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients | |
| Rowland et al. | Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure | |
| Loomans-Kropp et al. | Cancer prevention and screening: the next step in the era of precision medicine | |
| RU2012111231A (ru) | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK | |
| Shah et al. | Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer | |
| JP2010521154A5 (hr) | ||
| Gautschi et al. | Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry | |
| Lankheet et al. | Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib | |
| Reichardt et al. | Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial | |
| Riely et al. | Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib | |
| Shin et al. | EGFR mutation and brain metastasis in pulmonary adenocarcinomas | |
| Graf et al. | Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC | |
| Edin et al. | The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer | |
| Wilmott et al. | Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine | |
| Chan et al. | Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia | |
| JP2010521153A5 (hr) | ||
| Jeong et al. | HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF | |
| Seppälä et al. | Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response | |
| Gajate et al. | Influence of KRAS p. G13D mutation in patients with metastatic colorectal cancer treated with cetuximab | |
| Wang et al. | CC motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis | |
| Young et al. | A comparison of methods for EGFR mutation testing in non–small cell lung cancer | |
| Backen et al. | Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial |